Zetagen Therapeutics Announces First Patients Enrolled in Phase 2a Clinical Study of ZetaMet™ (Zeta-BC-003) Metastatic Breast Cancer
/
DateNov 12 2024
(400,000 patients annually are diagnosed with metastatic lytic bone lesions with only non-curative, palliative therapies available) ZetaMet™ (Zeta-BC-003) is a first-of-its kind molecular pathway designed... Read More →